The Impact of Malnutrition on Immune Responses to Tuberculosis

NCT ID: NCT05044910

Last Updated: 2024-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess immune responses to Mtb in children with MAM compared to well-nourished children and to evaluate the impact of a nutrition intervention on these immune responses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immune dysfunction in malnourished children is poorly characterised. The aim of this study is to assess immune responses to Mycobacterium tuberculosis (Mtb) in children with moderate acute malnutrition (MAM) compared to wellnourished children and to evaluate the impact of a nutrition intervention on these immune responses. Innate and adaptive immune responses to Mtb will be characterised in four groups: 1) MAM children with TB disease; 2) Wellnourished children with TB disease; 3) MAM children with latent TB infection; 4) Well-nourished children with latent TB infection. A range of assays to compare innate, adaptive and functional immune responses to TB between groups will be performed. Whether nutritional supplementation improves immune function in MAM children remains uncertain. Hence, children in all four groups will be followed up during 6 months of TB therapy/chemoprophylaxis. MAM children will receive 12 weeks of concomitant ready-to-use supplementary food, to evaluate longitudinal changes in innate and adaptive immune function, monocyte:lymphocyte ratio and mycobacterial growth inhibition. The results of this study will provide data to understand the reasons for infection susceptibility in malnourished children and provide a proof-of-concept that nutritional rehabilitation promotes immune rehabilitation. It will also provide a proof-of concept for use of nutritional supplementation as adjust therapy in TB disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malnutrition, Child Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MAM children with TB disease

Ready to Use supplementary food (RUSF)

Intervention Type DIETARY_SUPPLEMENT

Children with malnutrition will be given RUSF

Wellnourished children with TB disease

No interventions assigned to this group

MAM children with latent TB infection

Ready to Use supplementary food (RUSF)

Intervention Type DIETARY_SUPPLEMENT

Children with malnutrition will be given RUSF

Well-nourished children with latent TB infection

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ready to Use supplementary food (RUSF)

Children with malnutrition will be given RUSF

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 12-60 months
* HIV-negative
* BCG vaccinated
* Moderate acute malnutrition (WHZ -2 to -3 or MUAC 115 - 125mm ± HAZ \<-2)
* TB disease
* Latent TB infection

* Severe acute malnutrition (WHZ\<-3; MUAC\<115mm; bilateral oedema)
* Severe anaemia (Hb: \<7g/dl)
* Chronic infection (HIV, hepatitis B or C)
* Chronic disease (e.g. Crohn's disease)
* Feeding problems (eg cerebral palsy) that prevent ingestion of RUSF
* Known nut allergy
* MDR TB disease and contacts of MDR TB adults
Minimum Eligible Age

12 Months

Maximum Eligible Age

60 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Child Health, Madras Medical College, Chennai

UNKNOWN

Sponsor Role collaborator

Stanley Medical College

OTHER_GOV

Sponsor Role collaborator

Kanchi Kamakoti Childs Trust Hospital, Chennai, India

UNKNOWN

Sponsor Role collaborator

Queen Mary University of London

OTHER

Sponsor Role collaborator

London School of Hygiene and Tropical Medicine

OTHER

Sponsor Role collaborator

DBT, India

UNKNOWN

Sponsor Role collaborator

Tuberculosis Research Centre, India

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aishwarya Venkataraman, MRCPCH

Role: PRINCIPAL_INVESTIGATOR

ICMR-NIRT

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Child Health

Chennai, Tamil Nadu, India

Site Status

Government Stanley Medical College and Hospital

Chennai, Tamil Nadu, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

References

Explore related publications, articles, or registry entries linked to this study.

Venkataraman A, Shanmugam S, Balaji S, Mani K, Shanmugavel AK, Muthuramalingam K, Hissar S, Thiruvengadam K, Selladurai E, Smuk M, Hanna LE, Prendergast AJ. Comparison of two mycobacterial strains in performance of the whole blood mycobacterial growth inhibition assay in Indian children. Tuberculosis (Edinb). 2022 Dec;137:102255. doi: 10.1016/j.tube.2022.102255. Epub 2022 Aug 31.

Reference Type DERIVED
PMID: 36252397 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019037

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MTB cfDNA Levels in TBP
NCT05397730 ACTIVE_NOT_RECRUITING